To include your compound in the COVID-19 Resource Center, submit it here.

Abivax doubles on HIV reservoir readout

Abivax S.A.S. (Euronext:ABVX) rose €10.50 (114%) to €19.70 after it said results of a Phase IIa study showed ABX464 reduced HIV reservoirs in chronically infected HIV patients.The small molecule inhibits viral replication by

Read the full 339 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE